# Acurx Pharmaceuticals, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Acurx Pharmaceuticals, Inc.).

## Overview

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat Gram-positive bacterial infections. The company’s lead program, ibezapolstat, is designed to inhibit DNA polymerase IIIC, a target intended to selectively block Gram-positive bacteria and address antimicrobial resistance. Its pipeline is aimed at priority pathogens such as C. difficile, MRSA, VRE, drug-resistant Streptococcus pneumoniae, and anthrax-related threats. Acurx was founded in 2017, began operations in 2018, and remains in the development and regulatory stage with no commercial product revenue to date.

## Products & services

• Ibezapolstat antibiotic candidate for C. difficile
• GPSS® small-molecule antibiotic platform
• Preclinical antibiotic candidates for Gram-positive pathogens
• R&D programs targeting MRSA, VRE, DRSP, anthrax

- **Lead clinical antibiotic candidate** (70%) — Development of ibezapolstat for difficult-to-treat C. difficile infection.
- **Antibiotic discovery platform** (20%) — GPSS® chemistry and target-based discovery work for Gram-positive pathogens.
- **Preclinical pipeline** (10%) — Earlier-stage programs aimed at MRSA, VRE, DRSP and anthrax threats.

- Ibezapolstat, the lead antibiotic candidate for C. difficile
- GPSS® Gram-positive selective spectrum antibiotic platform
- Small-molecule antibiotics targeting DNA polymerase IIIC
- Preclinical programs for MRSA, VRE and DRSP
- Antibiotic research for anthrax-related biodefense pathogens

## Customers

Acurx does not currently sell approved products, so its near-term 'customers' are primarily regulators, clinical investigators, contract research organizations, and manufacturing partners that enable development of its pipeline. If ibezapolstat is approved, the commercial customer base would shift to hospitals, infectious disease physicians, and other healthcare providers treating C. difficile and other resistant Gram-positive infections. Reimbursement would also depend on third-party payors such as government programs and private insurers, which influence adoption and pricing. Because the company is still clinical-stage, customer demand is not yet a direct revenue driver; instead, regulatory progress and clinical data are the main value drivers.

- **Regulatory and clinical development ecosystem** (primary) — FDA, EMA, CROs, investigators and trial sites that support advancement of ibezapolstat through clinical and CMC milestones.
- **Hospital and acute-care providers** (primary) — Potential future buyers of an approved C. difficile therapy for hospitalized patients with difficult-to-treat infections.
- **Third-party payors** (secondary) — Government and private insurers that would influence reimbursement, formulary access and net pricing after approval.
- **Infectious disease specialists** (secondary) — Physicians who would prescribe the product based on efficacy, safety and resistance profile.

- Hospitals and inpatient providers treating severe C. difficile infections
- Infectious disease physicians who prescribe anti-infective therapies
- Third-party payors that determine reimbursement and access
- Clinical trial sites and CROs supporting development programs
- Regulators such as FDA and EMA that gate approval and market entry

## Geography

Acurx is headquartered in Staten Island, New York, and operates as a U.S.-based development company. Its regulatory and clinical work is centered in the United States, where it interacts with the FDA and conducts most of its development activities. The company also received positive scientific advice from the EMA in January 2025, indicating a meaningful European regulatory pathway for ibezapolstat. Because Acurx has no commercial revenue and no disclosed country revenue split, geography mainly matters through regulatory exposure, trial execution, and future market-access potential in the U.S. and Europe.

- Headquartered in Staten Island, New York, United States
- Primary regulatory interface is the U.S. FDA
- EMA scientific advice supports a potential EU development path
- Development activity is concentrated in the U.S. clinical ecosystem
- No disclosed commercial revenue geography because the company has no sales

## Strategy

Acurx’s strategy is centered on advancing ibezapolstat through late-stage clinical development and regulatory preparation for C. difficile infection. The company is using FDA and EMA feedback to de-risk the Phase 3 program and align its chemistry, manufacturing and controls package with approval expectations. A second strategic priority is preserving liquidity through equity financings, warrant exercises and other capital raises, since the business has no product revenue. Longer term, the company is building a broader antibiotic pipeline around its GPSS® platform to address additional Gram-positive priority pathogens and create optionality beyond the lead asset.

- **Complete late-stage development of ibezapolstat** (short-term) — The lead asset is the main source of future value and the clearest path to commercialization.
- **Maintain financing capacity** (short-term) — The company has no product revenue and depends on external capital to fund clinical and regulatory work.
- **Broaden the antibiotic pipeline** (medium-term) — A broader portfolio can reduce single-asset risk and increase long-term partnering or commercialization options.

- Advance ibezapolstat into and through Phase 3 development
- Use FDA and EMA feedback to reduce regulatory execution risk
- Strengthen CMC readiness for clinical and eventual commercial supply
- Fund operations through equity and other capital markets access
- Expand the GPSS® platform into additional Gram-positive targets

## Risks

Acurx faces the core risks typical of a clinical-stage biotech company: no approved products, no revenue, and heavy dependence on successful clinical and regulatory outcomes. The company’s lead program must clear Phase 3, manufacturing, and approval hurdles, and any setback could materially delay or eliminate commercialization. Because it funds operations through equity issuance, dilution and capital-market access are ongoing risks, especially if investor sentiment weakens or trial timelines slip. The business is also exposed to reimbursement pressure, anti-kickback and fraud-and-abuse compliance requirements, cybersecurity and data protection risks, and broader competition from larger pharmaceutical companies with greater resources.

- **Clinical-stage execution risk** [critical] — The company has limited operating history and must successfully complete development before any commercial revenue can be generated.
- **Financing and dilution risk** [high] — Operations are funded primarily through equity financings, warrant exercises and other capital raises rather than operating cash flow.
- **Regulatory approval risk** [critical] — FDA and EMA decisions determine whether the company can advance to commercialization and access markets.
- **Reimbursement and pricing pressure** [high] — Even approved antibiotics may face payer scrutiny, managed-care restrictions and pricing challenges.
- **Competition from larger pharmaceutical companies** [medium] — Competitors may have greater R&D, manufacturing, regulatory and commercialization resources.

- No approved products and no revenue create high dependence on future approvals
- Clinical trial failure or regulatory delay could eliminate the lead asset’s value
- Capital needs may force repeated equity raises and shareholder dilution
- Reimbursement pressure could limit uptake even if a product is approved
- Healthcare fraud and abuse laws constrain commercialization and contracting
- Competition from larger pharma and biotech firms with more resources
- Cybersecurity and privacy failures could disrupt operations and damage trust

## Accounting

The most important accounting issue for Acurx is that research and development costs are expensed as incurred, so clinical progress directly affects reported losses rather than being capitalized as an asset. The company also uses estimates for accrued expenses and share-based compensation, both of which can move materially quarter to quarter depending on trial activity, vendor invoices and equity awards. Because it has no product revenue, there is no meaningful revenue recognition complexity today, but future commercialization would introduce judgment around timing of sales, rebates and returns. Cash advances for future R&D services are deferred until the related services are received, which can shift expense timing across reporting periods and affect comparability.

- **Research and development expense recognition** — Affects operating loss and quarterly comparability
- **Accrued expenses** — Can materially change reported liabilities and expenses
- **Share-based compensation** — Affects net loss and operating expense presentation
- **Deferred R&D prepayments** — Shifts expense timing between periods

- R&D is expensed as incurred, so trial activity drives operating losses
- Accrued expenses require estimates for CROs, consultants and other vendors
- Share-based compensation can materially affect non-cash operating costs
- Cash advances for future R&D services are deferred until services are received
- No current product revenue means future revenue recognition will be a new judgment area

---

*Last updated: 2026-08-11T04:46:19.429886+00:00*